CDTX vs PSA · rev $1.3M vs rev $4.82B
Cidara Therapeutics Inc (CDTX) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
CDTX currently screens at market cap $6.96B. PSA currently screens at market cap $0.
Not investment advice. Open the CDTX and PSA stock pages for the full models.
Not investment advice.